Ozempic Vision Loss (NAION) Lawsuit

What Is NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy)?

NAION is a sudden loss of blood flow to the optic nerve — the nerve that transmits visual information from the eye to the brain. It typically presents as painless, sudden vision loss in one eye, often noticed upon waking. The affected eye may experience a loss of the upper or lower visual field, reduced visual acuity, and a relative afferent pupillary defect. NAION is sometimes called a 'stroke of the eye' because the mechanism is similar to a stroke — inadequate blood supply causing tissue damage. Unlike some eye conditions, NAION damage is largely irreversible. There is no proven treatment to restore vision once the optic nerve has been damaged.

The GLP-1 and NAION Connection

In July 2024, researchers at Harvard Medical School and Massachusetts Eye and Ear published a study in JAMA Ophthalmology that found patients prescribed semaglutide (Ozempic/Wegovy) had a significantly higher risk of developing NAION compared to non-users. The study analyzed medical records from over 16,000 patients and found the association held across both diabetic and non-diabetic populations. Proposed biological mechanisms include: rapid weight loss causing changes in blood viscosity, semaglutide's effects on vascular endothelial function, alterations in blood pressure regulation, and changes in the microvascular environment of the optic nerve head — an area already vulnerable due to its watershed blood supply.

The risk appears to be dose-dependent, with higher doses correlating to greater risk. Patients using GLP-1 drugs for weight loss (higher doses than diabetes management) may face elevated risk. Additional studies from multiple research institutions have corroborated the association, strengthening the scientific basis for litigation.

Ozempic Vision Loss Lawsuit Status

In December 2025, the Judicial Panel on Multidistrict Litigation (JPML) established a second federal MDL specifically for NAION and vision loss claims related to GLP-1 medications. This is separate from the existing Ozempic gastroparesis MDL. As of late 2025, approximately 2,947 lawsuits have been filed alleging NAION or other vision damage from semaglutide and tirzepatide products. Three bellwether trials have been scheduled for early 2026, with the first set for January, followed by trials in March and May. Defendants include Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound).

Who Qualifies for an Ozempic NAION Lawsuit

You may qualify if you used Ozempic, Wegovy, Rybelsus (semaglutide), Mounjaro, or Zepbound (tirzepatide) and were subsequently diagnosed with NAION, experienced sudden painless vision loss in one or both eyes, or were diagnosed with optic neuropathy during or after treatment. Key documentation includes: prescription records, ophthalmology records confirming NAION diagnosis (including OCT imaging and visual field testing), and a timeline showing the temporal relationship between GLP-1 use and vision loss onset.

Symptoms of GLP-1-Related Vision Loss

NAION symptoms typically appear suddenly and may include: painless loss of vision in one eye (often noticed upon waking), blurred or dimmed vision, loss of the upper or lower half of the visual field, difficulty with contrast sensitivity, and a sensation that vision is 'washed out.' Some patients experience sequential involvement of both eyes over weeks to months. If you experience any sudden vision changes while taking a GLP-1 medication, seek immediate ophthalmologic evaluation and inform your doctor about your medication use.

How This Differs From Ozempic Gastroparesis Claims

The Ozempic litigation now involves two separate MDLs with different injuries, evidence, and timelines. The gastroparesis MDL addresses gastrointestinal injuries — severe stomach paralysis, bowel obstruction, and related digestive damage. The NAION MDL addresses vision loss and optic nerve damage. Patients may have claims in one or both MDLs depending on their injuries. The two MDLs share the same defendants (Novo Nordisk, Eli Lilly) but involve different scientific evidence and expert witnesses.

Frequently Asked Questions

Can NAION vision loss be reversed?

Unfortunately, NAION-related vision loss is generally permanent. There is currently no proven treatment to restore vision once the optic nerve has been damaged. Some patients may experience partial improvement in the weeks following the event, but most retain some degree of permanent visual deficit.

Should I stop taking Ozempic if I'm worried about NAION?

Do not stop or change any medication without consulting your prescribing physician. Your doctor can evaluate your individual risk factors and discuss the benefits and risks of continuing treatment. If you experience any sudden vision changes, seek immediate medical attention.

What is the difference between the gastroparesis and NAION lawsuits?

They are separate MDLs with different injuries. The gastroparesis MDL covers digestive injuries like stomach paralysis and bowel obstruction. The NAION MDL covers vision loss from optic nerve damage. You may qualify for one or both depending on your injuries.

Does this affect Mounjaro and Wegovy users too?

Yes. The NAION MDL covers all GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Rybelsus (all semaglutide by Novo Nordisk), as well as Mounjaro and Zepbound (tirzepatide by Eli Lilly). The mechanism of injury is believed to be related to the GLP-1 drug class, not a specific brand.